Heart transplantation in cardiac amyloidosis

Abstract

It is known that the prognosis of patients affected by light-chain (AL) or transthyretin-related (TTR) amyloidosis is poor. TTR amyloidosis has usually shown a slower progression than AL amyloidosis, both hereditary TTR amyloidosis, where there is an inherited mutation in the DNA, and wild-type TTR amyloidosis, which usually affects the elderly. In this paper, the current literature about heart transplantation on cardiac amyloidosis patients is extensively reviewed. The two most frequent types of cardiac amyloidosis have been considered for heart transplantation: AL amyloidosis and wild-type TTR amyloidosis. According to this analysis, it is reasonable that heart transplantation may represent a valuable option in carefully selected patients. Moreover, it could improve prognosis, enabling autologous stem cell transplantation in the AL amyloidosis subgroup. In our humble opinion, it is mandatory to define a multidisciplinary approach to help select candidates to obtain the most effective results.

Keywords

Heart transplantation / cardiac amyloidosis / prognosis

References

[1] Vergaro G,Barison A.Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings.Eur J Prev Cardiol2020;27:1806-15

[2] Nienhuis HL,Hazenberg BP.The prevalence and management of systemic amyloidosis in western countries.Kidney Dis (Basel)2016;2:10-9 PMCID:PMC4946260

[3] Simões MV,Marcondes-braga FG.Posicionamento sobre diagnóstico e tratamento da amiloidose cardíaca - 2021.Arquivos Brasileiros de Cardiologia2021;117:561-98

[4] Debonnaire P,De Smet M.Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.Acta Cardiol2021:1-14

[5] Oubari S,Papathanasiou M.Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement.Eur J Haematol2021;107:449-57

[6] Elsayed M,Habib MH.Current updates on the management of AL amyloidosis.J Hematol2020;10:147-61 PMCID:PMC8425803

[7] Biliński J,Januszewicz A.Cardiac amyloidosis secondary to multiple myeloma: successful sequential cardiac and autologous stem cell transplantations with excellent outcome.Eur Heart J2021;42:3803

[8] Comenzo RL,Palladini G.Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.Leukemia2012;26:2317-25

[9] Tahir UA,Kim JS.Predictors of mortality in light chain cardiac amyloidosis with heart failure.Sci Rep2019;9:8552 PMCID:PMC6561903

[10] Palladini G,Merlini G.Management of AL amyloidosis in 2020.Hematology Am Soc Hematol Educ Program2020;2020:363-71 PMCID:PMC7727541

[11] Frustaci A,Verardo R.Kappa-light chain amyloid overlapping hypertrophic cardiomyopathy with myocardial noncompaction.Circ Cardiovasc Imaging2020;13:e010379

[12] Kumar SK,Lacy MQ.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Mayo Clin Proc2011;86:12-8 PMCID:PMC3012628

[13] Maurer MS,Comenzo R,Rapezzi C.Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis.Circulation2017;135:1357-77 PMCID:PMC5392416

[14] Hall R.Cardiac transplantation for AL amyloidosis.BMJ1994;309:1135-7 PMCID:PMC2541916

[15] Vaidya GN,Kittleson M.Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era.Clin Transplant2021;35:e14308

[16] Hosenpud JD,Griffith BP.Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicentre survey.J Heart Transplant1990;9:346-50

[17] Conner R,Norman DJ.Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease. J Heart Transplant 1988;7:165-7

[18] Kpodonu J,Caines A.Outcome of heart transplantation in patients with amyloid cardiomyopathy.J Heart Lung Transplant2005;24:1763-5

[19] Skinner M,Seldin DC.High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.Ann Intern Med2004;140:85-93

[20] Gillmore JD,Lachmann HJ.Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.Blood2006;107:1227-9

[21] Kristen AV,Schonland SO.Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis.Eur J Heart Fail2009;11:1014-20

[22] Okamoto S,Lindqvist P.Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients.Amyloid2011;18:200-5

[23] Sickels A,Ruch B.Combined heart-liver and domino liver transplantation in familial amyloidosis.Am Surg2021;:31348211023427

[24] Rosenbaum AN,Grogan M.Outcomes after cardiac transplant for wild type transthyretin amyloidosis.Transplantation2018;102:1909-13

[25] Mehra MR,Hannan MM.International Society for Heart Lung Transplantation (ISHLT) Infectious DiseasesPediatric and Heart Failure and Transplantation CouncilsThe 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update.J Heart Lung Transplant2016;35:1-23

[26] Roig E,Gonzalez-Vilchez F.Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 2009;9:1414-9.

[27] Lacy MQ,Hayman SR.Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.J Heart Lung Transplant2008;27:823-9

[28] Ohiomoba RO,Ezema A.Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.Am Heart J2021;236:13-21

[29] Di Nora C,Ferrara V.Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation.J Cardiovasc Med (Hagerstown)2021;22:261-7

[30] Gertz MA,Falk RH.Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18-22 April 2004.Am J Hematol2005;79:319-28

[31] Palladini G,Gertz MA.New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.J Clin Oncol2012;30:4541-9

[32] Kristen AV,Blum P.Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era.J Heart Lung Transplant2018;37:611-8

[33] Garcia-Pavia P,Brito D.Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy.Eur J Heart Fail2021;23:895-905 PMCID:PMC8239846

[34] Obici L,Buades J.European Network for TTR-FAP (ATTReuNET)Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.Curr Opin Neurol2016;29 Suppl 1:S27-35 PMCID:PMC4739313

[35] Garcia-Pavia P,Adler Y.Diagnosis and treatment of cardiac amyloidosis. A position statement of the European society of cardiology working group on myocardial and pericardial diseases.Eur J Heart Fail2021;23:512-26

[36] Davis MK,Witteles RM.Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy.J Heart Lung Transplant2015;34:658-66

[37] Maurer MS,Gundapaneni B.ATTR-ACT Study InvestigatorsTafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med2018;379:1007-16

[38] Müller ML,Heidecker B.Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?.Eur J Heart Fail2020;22:39-53

[39] Di Nora C,D’Elia AV.Heart transplantation in Danon disease: Long term single centre experience and review of the literature.Eur J Med Genet2020;63:103645

[40] Di Nora C,Miani D.Heart transplantation in kearns-sayre syndrome.Transplantation2019;103:e393-4

[41] Di Nora C, Livi U. Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis.Curr Opin Organ Transplant2020;25:211-7

[42] Maurer MS,Hesdorffer C.Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.Transplantation2007;83:539-45

[43] Dubrey SW,Hawkins PN.Cardiac transplantation for amyloid heart disease: the United Kingdom experience.J Heart Lung Transplant2004;23:1142-53

[44] Grogan M,McCurdy A.Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo clinic experience.World J Transplant2016;6:380-8 PMCID:PMC4919742

[45] Barrett CD,Zhao H.Outcomes in patients with cardiac amyloidosis undergoing heart transplantation.JACC Heart Fail2020;8:461-8

[46] Mignot A,Redonnet M.Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.Arch Cardiovasc Dis2008;101:523-32